Bio Plus Co., Ltd (KOSDAQ:099430)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,890.00
-150.00 (-2.13%)
Jun 27, 2025, 3:30 PM KST
24.82%
Market Cap 405.62B
Revenue (ttm) 79.78B
Net Income (ttm) 19.60B
Shares Out 58.87M
EPS (ttm) 333.28
PE Ratio 20.67
Forward PE n/a
Dividend 50.00 (0.73%)
Ex-Dividend Date Dec 27, 2024
Volume 312,445
Average Volume 479,756
Open 7,020.00
Previous Close 7,040.00
Day's Range 6,870.00 - 7,110.00
52-Week Range 4,385.00 - 8,420.00
Beta 0.55
RSI 40.62
Earnings Date Aug 14, 2025

About Bio Plus

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; S... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2003
Employees 121
Stock Exchange KOSDAQ
Ticker Symbol 099430
Full Company Profile

Financial Performance

In 2024, Bio Plus's revenue was 66.41 billion, an increase of 2.10% compared to the previous year's 65.04 billion. Earnings were 14.15 billion, a decrease of -44.68%.

Financial Statements

News

There is no news available yet.